[HTML][HTML] Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
X Wu, S Matosevic - Molecular Therapy-Oncolytics, 2022 - cell.com
Treatment of many cancers, particularly those that remain difficult to treat or are refractive
after standard-of-care therapies, has been challenging with cell-based therapies. Although …
after standard-of-care therapies, has been challenging with cell-based therapies. Although …
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy.
X Wu, S Matosevic - Molecular Therapy Oncolytics, 2022 - europepmc.org
Treatment of many cancers, particularly those that remain difficult to treat or are refractive
after standard-of-care therapies, has been challenging with cell-based therapies. Although …
after standard-of-care therapies, has been challenging with cell-based therapies. Although …
[HTML][HTML] Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
X Wu, S Matosevic - Molecular Therapy Oncolytics, 2022 - ncbi.nlm.nih.gov
Abstract Treatment of many cancers, particularly those that remain difficult to treat or are
refractive after standard-of-care therapies, has been challenging with cell-based therapies …
refractive after standard-of-care therapies, has been challenging with cell-based therapies …
[HTML][HTML] Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
X Wu, S Matosevic - Molecular Therapy-Oncolytics, 2022 - Elsevier
Treatment of many cancers, particularly those that remain difficult to treat or are refractive
after standard-of-care therapies, has been challenging with cell-based therapies. Although …
after standard-of-care therapies, has been challenging with cell-based therapies. Although …
Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
X Wu, S Matosevic - Molecular therapy oncolytics, 2022 - pubmed.ncbi.nlm.nih.gov
Treatment of many cancers, particularly those that remain difficult to treat or are refractive
after standard-of-care therapies, has been challenging with cell-based therapies. Although …
after standard-of-care therapies, has been challenging with cell-based therapies. Although …
[引用][C] Gene-edited and CAR-NK cells: Opportunities and challenges with engineering of NK cells for immunotherapy
X Wu, S Matosevic - europepmc.org
Treatment of many cancers, particularly those that remain difficult to treat or are refractive
after standard-of-care therapies, has been challenging with cell-based therapies. Although …
after standard-of-care therapies, has been challenging with cell-based therapies. Although …